|Mr. Masayuki Mitsuka||Member of the Board||N/A||N/A||1954|
|Mr. Hiroaki Ueno||Pres & Representative Director||N/A||N/A||1958|
|Megumi Ohtaki||Exec. Officer & Chief Compliance Officer||N/A||N/A||N/A|
|Yoshiaki Takai||VP & Head of Corp. Communications Department||N/A||N/A||N/A|
|Yasutoshi Kawakami||Exec. Officer and Head of Sale & Marketing Division||N/A||N/A||N/A|
Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan, Europe, North America, other Asian countries, and internationally. The company primarily offers drugs for immuno-inflammation, diabetes and kidney, and central nervous system diseases; vaccines; and OTC products. It offers Simponi, a treatment agent for rheumatoid arthritis (RA); Canalia, Invokana, Tenelia, and Canaglu, treatment agents for type 2 diabetes mellitus; Stelara and Amiselimod for treatment of Crohn's disease; Radicava, an amyotrophic lateral sclerosis (ALS) treatment agent; Gilenya, a treatment agent for multiple sclerosis; and Remicade for treatment of RA, Crohn's disease, and various inflammatory autoimmune diseases. The company also provides Lexapro, an anti-depressant agent; Imusera for multiple sclerosis; Rupafin, an oral allergy treatment agent; Talion, an anti-allergic agent; Fasinumab, a human anti-NGF monoclonal antibody; Dersimelagon for immnuno-inflammation; Vadadustat, for treatment of renal anemia; and Apararenone, for treatment of non-alcoholic steatohepatitis. In addition, it offers vaccines, such as influenza vaccine, Tetrabik, Mearubik, Varicella vaccine, and JEBIK V. The company has collaborations with Dyadic International, Inc.; Hitachi Ltd.; HitGen Ltd.; and Viela Bio, Inc. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.
Mitsubishi Tanabe Pharma Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.